Composition

• 30 teacher-researchers, researchers, engineers, technicians
• 18 graduate students, 3 undergraduate students

  Facilities

• Intestinal models: cell lines, human intestinal explants, experimental colitis
• Mass spectrometric analysis and in vivo isotopic studies, proteomics
• Rodent and human DEXA
• Digestive function investigation platform (motility, sensitivity, endoscopy)
• Neurostimulation and neuronavigation systems

  Activity

The works of our group, integrated to the IFRMP, are mainly dedicated to the study of eating disorders, irritable bowel syndrome (IBS) and inflammatory bowel diseases (IBD). These pathologies share common features of intestinal inflammation and dysregulation of the gut-brain axis and offer great opportunities for innovative therapeutic strategies (immunonutrition, neurostimulation). Our investigations explore the underlying mechanisms of these diseases from the molecular level to clinical trials. This broad range of research from the bench to the bedside is the result of our research strategy that brings together basic and clinical sciences, in a tight collaboration between laboratory scientists and health professionals. Our dynamic research team has an active research strategy which also drives the translation of research from the laboratory to patenting and creation of biotech companies entrepreneurship.

  Main contributions

• Study and nutritional modulation of gut protein metabolism under inflammatory conditions: IBD, IBS and eating-disorders
• Study of dysregulation of gut-brain axis (eatingdisorders, IBS): role of intestinal barrier in the production of autoantibodies against neuropeptides involved in eating disorders and digestive diseases
• Development of innovative formula for intestinal inflammation-targeted nutrients or drugs and of central or peripheric neurostimulation techniques

  Latest publications

2018

• Charpentier C, Chan R, Salameh E, Mbodji K, Ueno A, Coëffier M, Guérin C, Ghosh S, Savoye G, and Marion-Letellier R. Dietary n-3 PUFA May Attenuate Experimental Colitis. Mediators Inflamm 2018, 2018: 8430614.
  29670469
• Melchior C, Bril L, Leroi AM, Gourcerol G, and Ducrotté P. Are characteristics of abdominal pain helpful to identify patients with visceral hypersensitivity in irritable bowel syndrome? Results of a prospective study. Neurogastroenterol Motil 2018
  29345401
• Sacleux SC, Sarter H, Fumery M, Charpentier C, Guillon-Dellac N, Coevoet H, Pariente B, Peyrin-Biroulet L, Gower-Rousseau C, and Savoye G; EPIMAD Group. Post-operative complications in elderly onset inflammatory bowel disease: a population-based study. Aliment Pharmacol Ther 2018
  29737553
• Tavolacci MP, Delay J, Grigioni S, Déchelotte P, and Ladner J. Changes and specificities in health behaviors among healthcare students over an 8-year period. PLoS One 2018, 13: e0194188.
  29566003

2017

• Ghouzali I, Lemaitre C, Bahlouli W, Azhar S, Bôle-Feysot C, Meleine M, Ducrotté P, Déchelotte P and Coëffier M. Targeting immunoproteasome and glutamine supplementation prevent intestinal hyperpermeability. Biochim Biophys Acta 2017, 1861: 3278-3288.
  27544233
• Langlois LD, Le Long E, Meleine M, Antor M, Atmani K, Dechelotte P, Leroi AM, and Gourcerol G. Acute sacral nerve stimulation reduces visceral mechanosensitivity in a cross-organ sensitization model. Neurogastroenterol Motil 2017, 29:  10.1111/nmo.
  27997083
• Marion-Letellier R, Bohn P, Modzelewski R, Vera P, Aziz M, Guérin C, Savoye G and Savoye-Collet C. SPECT-computed tomography in rats with TNBS-induced colitis: A first step toward functional imaging. World J Gastroenterol 2017, 23: 216-223.
  28127195